Efficacy News and Research

RSS
Intranasal COVID-19 therapeutic shows promise in preclinical trials

Intranasal COVID-19 therapeutic shows promise in preclinical trials

WHO’s new guidance sets essential standards to fight malaria, other vector-borne diseases

WHO’s new guidance sets essential standards to fight malaria, other vector-borne diseases

Does cross-immunity exist between SARS-CoV-2 B.1.1.28 and P.1 variants?

Does cross-immunity exist between SARS-CoV-2 B.1.1.28 and P.1 variants?

A SARS-CoV-2 vaccine candidate based on B.1.351 spike trimer shows broad neutralizing capability

A SARS-CoV-2 vaccine candidate based on B.1.351 spike trimer shows broad neutralizing capability

Early treatment may prevent clotting in COVID-19 vaccine-related thrombocytopenia

Early treatment may prevent clotting in COVID-19 vaccine-related thrombocytopenia

Plant-produced COVID-19 vaccine shows potent immunogenic profile in humans

Plant-produced COVID-19 vaccine shows potent immunogenic profile in humans

SARS-CoV-2 vaccines from Pfizer-BioNTech and AstraZeneca reduce mortality among the elderly

SARS-CoV-2 vaccines from Pfizer-BioNTech and AstraZeneca reduce mortality among the elderly

The effects of SARS-CoV-2 vaccination on pregnancy and birth

The effects of SARS-CoV-2 vaccination on pregnancy and birth

Human monoclonal antibodies neutralize SARS-CoV-2 in an Fc-independent manner

Human monoclonal antibodies neutralize SARS-CoV-2 in an Fc-independent manner

Pfizer/BioNTech COVID-19 vaccine induces a stronger antibody response when given at an extended interval

Pfizer/BioNTech COVID-19 vaccine induces a stronger antibody response when given at an extended interval

Virtual analysis identifies a potential natural inhibitor of SARS-CoV-2 Nsp15

Virtual analysis identifies a potential natural inhibitor of SARS-CoV-2 Nsp15

Spike antibodies after vaccination with Pfizer and Oxford vaccines

Spike antibodies after vaccination with Pfizer and Oxford vaccines

Presence of Anti-SARS-CoV-2 antibodies after 13 months of infection

Presence of Anti-SARS-CoV-2 antibodies after 13 months of infection

Expert panel provides guidance for optimized design of early drug trials for Alzheimer's, related dementias

Expert panel provides guidance for optimized design of early drug trials for Alzheimer's, related dementias

Methotrexate impairs immunogenicity of BNT162b2 SARS-CoV-2 vaccine in patients with immune-mediated inflammatory diseases

Methotrexate impairs immunogenicity of BNT162b2 SARS-CoV-2 vaccine in patients with immune-mediated inflammatory diseases

SARS-CoV-2 mRNA vaccine PTX-COVID19-B safe and highly immunogenic in preclinical study

SARS-CoV-2 mRNA vaccine PTX-COVID19-B safe and highly immunogenic in preclinical study

ErbB inhibitor lapatinib exhibits potent anti-SARS-CoV-2 activity

ErbB inhibitor lapatinib exhibits potent anti-SARS-CoV-2 activity

Moderna's COVID-19 vaccine elicits six-month antibody responses to variants

Moderna's COVID-19 vaccine elicits six-month antibody responses to variants

Hyperinvasive approach is an effective treatment strategy for out-of-hospital cardiac arrest

Hyperinvasive approach is an effective treatment strategy for out-of-hospital cardiac arrest

Delaying second dose of covid-19 vaccine could result in lower mortality under certain conditions

Delaying second dose of covid-19 vaccine could result in lower mortality under certain conditions

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.